British Biotech licenses ImmunoGen's cancer drug;terminated
Broadening its cancer platform, British Biotech has licensed exclusive Japanese and European Union rights to ImmunoGen's tumor-activated prodrug, huN901-DM1, for small-cell lung cancer, paying an up-front fee of (uf)$1.5mm, plus royalties on sales in these territories.
- Drug Delivery
- Includes Contract
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com